



Joab Trujillo
AB Enzymes Inc.
8211 W. Broward Blvd., Suite 375
Plantation, FL 33324

Re: GRAS Notice No. GRN 001121

Dear Mr. Trujillo,

The Food and Drug Administration (FDA, we) is granting the request to cease our evaluation of GRN 001121, which we filed on May 8, 2023. We received this request on February 7, 2024.

The subject of the notice is fructanase enzyme preparation produced by *Trichoderma reesei* expressing the gene encoding fructanase from *Lactobacillus sp.* (fructanase enzyme preparation) for use as an enzyme at up to 12 mg total organic solids (TOS)/kg raw material in baking. The notice informs us of AB Enzymes Inc.'s view that this use of fructanase enzyme preparation is GRAS through scientific procedures.

In a teleconference on February 7, 2024, we informed you that we had identified areas of the safety narrative that would require edits beyond the intended scope of the GRAS notice evaluation process. We noted that the focus of the safety narrative should shift to the fructanase enzyme in the preparation, while the information supporting the safety of the production organism provided in the notice will remain a part of the revised safety narrative. We recommended that you request that we cease our evaluation of GRN 001121 and resubmit a new GRAS notice with a revised safety narrative. In an email dated February 7, 2024, you requested that we cease our evaluation of GRN 001121.

In accordance with 21 CFR 170.275(b)(3), the text of this letter responding to GRN 001121 is accessible to the public at www.fda.gov/grasnoticeinventory.

Sincerely,

Susan J.
Carlson -S

Digitally signed by Susan
J. Carlson -S
Date: 2024.02.15
19:05:09 -05'00'

Susan J. Carlson, Ph.D.
Director
Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety
and Applied Nutrition

U.S. Food and Drug Administration
Center for Food Safety & Applied Nutrition
5001 Campus Drive
College Park, MD 20740
www.fda.gov